The FDA expert panel recommended the use of molnupiravir

The FDA expert panel recommended the use of molnupiravir 4
The FDA expert panel recommended the use of molnupiravir 4

With this move, molnupiravir could be approved in the US in the next few days and officially used before the end of this year.

On November 26, pharmaceutical company Merck said the antiviral drug molnupiravir reduces the risk of hospitalization and death in Covid-19 patients by 30% (lower than the previous estimate of 50%).

Dr. David Boulware, an infectious disease expert at the University of Minnesota, expects regulators to authorize the drug.

He said molnupiravir could be considered a low-level treatment drug, an alternative for people who cannot use other methods.

The antiviral drug molnupiravir is developed by two companies Merck and Ridgeback Biotherapeutics.

Molnupiravir interrupts the process of nCoV replication.

Britain was the first country in the world to approve molnupiravir on November 4.

Based on clinical trial data, the drug is most effective when taken in the early stages of Covid-19 and the MHRA recommends using the drug within five days of the onset of symptoms.

Merck plans to produce 10 million treatment courses of the drug by the end of the year, with production increasing in 2022. In June, the pharmaceutical company signed a supply agreement worth 1.2 billion USD with the US government.

Molnupiravir is also being tested in phase 3 in Vietnam, piloted by the Ministry of Health to be included in the F0 home treatment kit.

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *